<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36302">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633969</url>
  </required_header>
  <id_info>
    <org_study_id>IND2-15-08</org_study_id>
    <nct_id>NCT02633969</nct_id>
  </id_info>
  <brief_title>Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to &lt;17 Years of Age</brief_title>
  <official_title>A Phase IIA, Open-label, Safety and Pharmacokinetic Study of Indomethacin Capsules in Pediatric Subjects 6 to &lt;17 Years of Age With Mild to Moderate Acute Postoperative Pain Following Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iroko Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iroko Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to evaluate the safety and tolerability and to model the
      single-dose pharmacokinetic profile of indomethacin capsules low dose and high dose in
      children ages 6 to &lt;17 years experiencing mild to moderate acute postoperative pain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentrations of indomethacin</measure>
    <time_frame>0-12 hours after first dose of indomethacin</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Indomethacin Capsules low dose and high dose as assessed by the incidence of adverse events from baseline to Day 3 or early termination</measure>
    <time_frame>Baseline to Day 3/Early Termination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Indomethacin Capsules low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin Capsules low dose twice daily for up to three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indomethacin Capsules high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin Capsules high dose twice daily for up to three days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin Capsules low dose</intervention_name>
    <arm_group_label>Indomethacin Capsules low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin Capsules high dose</intervention_name>
    <arm_group_label>Indomethacin Capsules high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight â‰¥20 kilograms

          -  Mild to moderate acute pain requiring treatment with analgesic medication

          -  Willing to have blood samples taken for PK sampling using an indwelling catheter

          -  Must be able to swallow capsules and can tolerate oral medication

          -  For females: is not of reproductive potential (defined as premenarchal) or is
             practicing an acceptable method of birth control

        Exclusion Criteria:

          -  Severe acute pain

          -  Chronic analgesic or glucocorticoid use for any condition within 6 months before
             dosing with study drug

          -  Emergency surgery

          -  History of allergic reaction, hypersensitivity, or clinically significant intolerance
             to indomethacin, aspirin, codeine, acetaminophen, or any NSAID

          -  History of peptic ulcer disease or a GI event (eg, perforation, obstruction, or
             bleed) within 6 months before screening

          -  Current use of any medication that may cause a clinically significant drug
             interaction when co-administered with indomethacin

          -  Current use of any medication that might affect the pharmacokinetics of indomethacin

          -  History of bleeding disorders

          -  Developmental delay or behavioral problems that would make it difficult to assess
             pain

          -  Impaired liver function

          -  Clinically significant renal or cardiovascular disease

          -  Any medical condition that compromises ability to swallow, absorb, metabolize, or
             excrete the study drug

          -  Previously received any investigational product or device within 30 days before
             Screening or scheduled to receive an investigational device or another
             investigational drug (other than that in this study) during the course of this study

          -  Previous participation in this clinical study or currently taking indomethacin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 27, 2017</lastchanged_date>
  <firstreceived_date>December 15, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
